drugset
Drugs / Nonavalent HPV study vaccine
last change Jan 2026 re-read 9 days ago

Nonavalent HPV study vaccine

also known as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

Vaccine

Developed for
human papilloma virus infection
Investigated by
Beijing Health Guard Biotechnology, Inc · Dr. M Djamil Hospital, Padang · University of Muhammadiyah Malang Hospital

Trials 1

today NCT06207175 · Ph 3
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06207175 Nov 2023 → Nov 2024 human papilloma virus infection Beijing Health Guard Biotechnology, Inc Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Nonavalent HPV study vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06207175 ↗
Known as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) “Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)” NCT06207175 ↗
Modality Vaccine “Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine” NCT06207175 ↗
Route Intramuscular “Administered Intramuscularly” NCT06207175 ↗